Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide
In patients with MASH and either overweight or obesity, semaglutide was associated with a clinically and statistically significant reduction in ALT after 6 months of continuous use. Reductions in AST, weight, and HbA1c were also observed.
Authors
- Firas Dabbous (ORCID: https://orcid.org/0000-0002-0823-6099)
- Abdalla Aly (ORCID: https://orcid.org/0000-0001-7411-894X)
- Samuel Huse (ORCID: https://orcid.org/0009-0001-7633-2293)
- Husam Albarmawi (ORCID: https://orcid.org/0000-0001-8870-0842)
- Eric Lawitz (ORCID: https://orcid.org/0000-0002-4234-224X)
- Andres Quintero (ORCID: https://orcid.org/0000-0002-0405-6445)
- Alia Yousif
- Maximilian Jara (ORCID: https://orcid.org/0000-0002-1245-9869)
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Novo Nordisk (United Kingdom) (GB)
- Texas Liver Institute (US)
- Thermo Fisher Scientific (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/03007995.2025.2596430
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00